October 4-5, 2021 Webconference

The Longwood Healthcare Leaders meeting, October 4-5, 2021, centered on Harvard Medical School via webconference, brings together leading biopharma CEOs, heads of R&D, top academic researchers, and healthcare investors for an off-the-record forum focused on accelerating the translation of discoveries into medicines to help patients.

Speakers include FDA Commissioner Janet Woodcock, MA Governor Charlie Baker, Takeda CEO Christophe Weber, Harvard Med Dean George Daley, Bayer Pharmaceuticals CEO Stefan Oelrich, Janssen Global Head of R&D Mathai Mammen, Broad Institute Senior Fellow Mary Lynne Hedley, Biogen head of R&D Al Sandrock, BMS Research & Early Development head Rupert Vessey, Sanofi global research head & CSO Frank Nestle, Moderna co-founder Bob Langer, Amgen R&D head Dave Reese, among others.

These meetings are off-the-record and focused on accelerating the translation of discoveries into medicines to help patients; substantial donations enabled by these meetings benefit Life Science Cares, The Boston Foundation, BSO, Harvard Medical School, MIT, and other charities.

LONGWOOD HEALTHCARE LEADERS | AGENDA | OCTOBER 4 - 5, 2021

-- all times Eastern Standard –

 

MONDAY, OCTOBER 4, 2021 | DRAFT AGENDA

 

7:00 – 7:30 | LONGWOOD FUND INTRODUCTION

 

7:30 – 8:00 | NEWCO TO ESTABLISHED: BUILDING A BIOTECH
Philip Astley-Sparke, CEO, Replimune; David Donabedian, CEO, ImmuneID; Jeff Goldberg, CEO, Immunitas; Chad Shear, Principal, Fish & Richardson

 

8:00 – 8:30 | R&D COLLABORATION
Steve Hitchcock, Head, Research, Takeda; Philip Larsen, Global Head, Research & Early Development, Bayer Pharmaceuticals; Raquel Mura, Head, R&D, North America, Sanofi; Tarek Samad, SVP & Global Head, Research, Lundbeck; Rupert Vessey, President, Research & Early Development, Bristol Myers Squibb; John Westwood, Managing Director, Huron

 

8:30 – 8:50 | FIRESIDE CHAT

 

8:50 – 9:20 | SPOTLIGHT: HARVARD MEDICAL INNOVATION
George Church, Professor, Harvard Medical School; George Daley, Dean, Harvard Medical School; David Walt, Professor, Biologically Inspired Engineering, Harvard Medical School; Kai Wucherpfennig, Professor, Neurology, Harvard Medical School, Scientific Co-Founder, Immunitas

 

9:20 – 9:50 | HOW M&A SPURS INNOVATION 
Juergen Eckhardt, Head, Leaps, Bayer; Diana Gallagher, Head, External Innovation & New Indications, Biogen; Ivana Magovcevic-Liebisch, CEO, Vigil Neuroscience; Jeremy Levin, CEO, Ovid Therapeutics

 

9:50 – 10:20 | EXPEDITING RESEARCH FOR TREATMENTS AND CURES
John Connolly, CSO, Parker Institute; Lynn Kramer, Chief Clinical Officer, Eisai; Laura Sepp-Lorenzino, CSO, Intellia; Brad Margus, CEO, Cerevance

 

10:20 – 10:40 | FIRESIDE CHAT
Bill Anderson, CEO, Roche Pharmaceuticals; Christophe Weber, CEO, Takeda


10:40 – 11:10 | SOURCING AND IDENTIFYING NOVEL TECHNOLOGY
Paola Arlotta, Chair, Stem Cell & Regenerative Biology, Harvard Medical School; Niels Emmerich, VP, Global Head Search & Evaluation, AbbVie; Michal Preminger, Head, East North America, Johnson & Johnson Innovation; Mark Stevenson, COO, Thermo Fisher Scientific

 

11:10 – 11:40 | PUBLIC-PRIVATE PARTNERSHIPS
PJ Brooks, Program Director, Rare Diseases, NIH; Patrick Verheyen, Global Head, BD, Janssen

 

11:40 – 12:00 | REGULATORY KEYNOTE
Janet Woodcock, Commissioner, FDA

 

12:00 – 12:30 | CREATING A WORLD WITHOUT DISEASE
Ivan Cheung, US Chair, Global President, Neurology, Eisai; Mike Devoy, CMO, Bayer; Bill Hait, Global Head, External Innovation, Johnson & Johnson Innovation; Reed Jobs, Managing Director, Health, Emerson Collective

 

12:30 – 1:00 | GLOBAL MARKETS: WORKING ACROSS BORDERS
Hafrun Fridriksdottir, Executive Vice President, Global R&D, Teva; Philippe Lopes-Fernandes, CBO, Ipsen

 

1:00 – 1:30 | ADVANCING PLATFORM TECHNOLOGIES

Aoife Brennan, CEO, Synlogic; Christina Coughlin, CMO, Rubius Therapeutics; ; Annalisa D’Andrea, CSO, ImmuneID; Pearl Huang¸ CEO, Cygnal Therapeutics; Alise Reicin, CEO, Tectonic

 

1:30 – 1:50 | FIRESIDE CHAT
Mathai Mammen
, Global Head, R&D, Janssen Pharmaceuticals

 

1:50 – 2:20 | PREPARING FOR THE FUTURE OF R&D
Ray Deshaies, SVP, Global Research, Amgen; Frank Nestle, Global Head, Research & CSO, Sanofi; Andy Plump, President, R&D, Takeda; Luigi Gentile, CRO, BenchSci

 

2:20 – 2:50 | DESIGNING THE DEAL
Alban de La Sabliere
, SVP, Global Head, Partnering, Sanofi; Nouhad Husseini, SVP, Head, BD, Regeneron; Tim Shannon, General Partner, Canaan

 

2:50 – 3:20 | INNOVATION IN CELL THERAPY
Diana Brainard, CEO, AlloVir; Paul Lammers, CEO, Triumvira; Armon Sharei, CEO, SQZ Biotech; Joanne Smith-Farrell, CEO, Be Biopharma; Pascal Touchon, CEO, Atara; Maria Whitman, Head, Pharma, ZS Associates

 

3:20 – 3:40 | FIRESIDE CHAT
Al Sandrock, Head, R&D, Biogen

 

3:40 – 4:10 | MAKING A BIG IMPACT WITH LIMITED RESOURCES

Al Beardsley, COO, Galera; Roger Tung, CEO, Concert Pharmaceuticals

4:10 – 4:40 | ACCELERATING DRUG DEVELOPMENT
Jennifer Buell, President & COO, Agenus; Paulo Fontoura, Global Head & SVP Rare Diseases, Roche; Al Gianchetti, CEO, XyloCor; JC Gutierrez-Ramos, SVP & CSO, Danaher Corporation; Aaron Mitchell, R&D Excellence Practice Lead, ZS Associates

 

4:40 – 5:10 | NOVEL APPROACHES TO DRUG DISCOVERY

Bobby Azamian, CEO, Tarsus

5:10 – 5:40 | MAKING SMART INVESTMENTS
Ansbert Gadicke, Managing Director, MPM Capital; Bob Nelsen, Managing Director, ARCH Venture Partners; Dan Omstead, CEO, Tekla Capital Management; Priyanka Rohatgi, Venture Partner, Longwood Fund

 

5:40 – 6:00 | LONGWOOD FUND SUMMARY

 

 

TUESDAY, OCTOBER 5, 2021

 

7:00 – 7:30 | LONGWOOD FUND INTRODUCTION

 

7:30 – 8:00 | HARNESSING BIOMEDICAL INNOVATION
Sekar Kathiresan, CEO, Verve; Denitsa Milanova, CEO, Marble Therapeutics; Chandra Ramanathan, Global Head, Pharma R&D, Open Innovation, Bayer; Skip Virgin, CSO, Vir Biotechnology, NAS

 

8:00 – 8:20 | MODERATED KEYNOTE

Charlie Baker, Governor, Massachusetts


8:20 – 8:50 | HEALTH SYSTEMS IN A NEW ERA

Laurie Glimcher, CEO, Dana-Farber Cancer Institute; Tom Sequist, Chief Patient Experience & Equity Officer, Mass General Brigham

 

8:50 – 9:20 | BIG BIOPHARMA R&D
Christian Rommel
, Head, R&D, Bayer Pharmaceuticals

 

9:20 – 9:50 | ACCELERATING THE PATH TO PATIENT CARE
Fred Hassan, former Chair & CEO, Pharmacia, Schering-Plough; Kabir Nath, CEO, Otsuka; Melinda Richter, Global Head, JLabs, Johnson & Johnson Innovation

 

9:50 – 10:20 | DEVELOPING A WORLD-CLASS BOARD
Bill Heiden, Chair, Third Pole Therapeutics; Cathy Sohn, Director, BioEclipse Therapeutics; Julie Kampf, CEO, JBK Associates

 

10:20 – 10:40 | FIRESIDE CHAT
Barry Greene
, CEO, Sage Pharmaceuticals


10:40 – 11:10 | SCIENTIFIC INNOVATION: LAUNCHING COMPANIES FROM ACADEMIA
John Flavin, CEO, Portal Innovations; Phil Johnson, CEO, Interius BioTherapeutics; Lloyd Minor, Dean, Stanford School of Medicine

11:10 – 11:40 | CLINICAL TRIAL EFFICIENCY

Brent Vaughan, CEO, Cognito Therapeutics

 

11:40 – 12:10 | PERSISTENCE: THE LONG ROAD TO DRUG APPROVAL

Clay Siegall, CEO, SeaGen; Zhen Su, SVP, Head, Global Oncology, Merck KGaA

 

12:10 – 12:30 | FIRESIDE CHAT

Stefan Oelrich, CEO, Bayer Pharmaceuticals

12:30 – 1:00 | INNOVATIVE PARTNERSHIPS

Bram Goorden, COO, SOPHiA GENETICS; Jason Kelly, CEO, Ginkgo Bioworks

 

1:00 – 1:30 | ACTIONABLE DIVERSITY, INCLUSION, AND EQUITY IN HEALTHCARE
Ted Love, CEO, Global Blood Therapeutics; Maria Rivas, CMO, EMD Serono

 

1:30 – 2:00 | NOVEL THERAPEUTIC MODALITIES

Rachel Humphrey, CMO, Black Diamond Therapeutics; Brian McVeigh, CEO, Code Bio; Brett Monia, CEO, Ionis; Rick Morgan, CSO, Be Biopharma; Anabella Villalobos, SVP, Biotherapeutics & Medicinal Sciences, Biogen

 

2:00 – 2:20 | FIRESIDE CHAT
Bob Langer, Co-Founder, Moderna/Momenta, NAS

 

2:20 – 2:50 | EVOLVING BUSINESS STRATEGIES: THE SPIN OUT
Errik Anderson, CEO, Alloy Therapeutics; Myrtle Potter, CEO, Sumitovant

 

2:50 – 3:20 | FROM DATA TO MEDICINE
Michael Mina, Asst. Professor, Epidemiology, Harvard School of Public Health; Paul Schimmel, Professor, Cell & Molecular Biology, Scripps

 

3:20 – 3:40 | FIRESIDE CHAT

David Reese, EVP, R&D, Amgen

 

3:40 – 4:10 | INCORPORATING NOVEL DIAGNOSTIC APPROACHES

Kevin Conroy, CEO, Exact Sciences; Priti Hegde, CSO, Foundation Medicine; Jason Myers, CEO, ArcherDX

 

4:10 – 4:40 | APPROACHES TO REGULATORY HURDLES

Peter Hutt, former General Counsel, FDA; Niels Riedemann, CEO, InflaRx

 

4:40 – 5:00 | LONGWOOD FUND UPDATE

 

5:00 – 5:30 | EXTERNAL INNOVATION
Mary Lynne Hedley, Senior Fellow, Broad Institute, MIT; Lara Sullivan, CEO, Pyxis Oncology

 

5:30 – 6:00 | PREDICTING SUCCESSFUL INVESTMENTS
Lucio Iannone, Director, Leaps, Bayer; Aleks Radovic-Moreno, Partner, Longwood Fund; Kyle Lefkoff, General Partner, Boulder Ventures

Supporters

We are grateful to the following organizations for their support of this meeting. To learn more about getting involved contact susan@longwoodfund.com